Epilepsy, Generalized
12 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Brain Diseases, Epilepsy, Nervous System Diseases
Narrower: Epilepsies, Myoclonic 7, Epilepsy, Absence 2, Myoclonic Epilepsy, Juvenile 1, Spasms, Infantile 2
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 30mg PRAX-628 for epilepsy, generalized | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivaracetam for epilepsy, absence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for epilepsy, absence | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| ETX101 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ION337 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JZP926 capsule for myoclonic epilepsy, juvenile | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relutrigine for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STK-001 - Single Ascending Doses for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zorevunersen for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.